Phase II study evaluating trifluridine/tipiracil plus bevacizumab and capecitabine plus bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis

被引：9
|
作者：
Lesniewski-Kmak, K. [1 ]
Moiseenko, V. [2 ]
Saunders, M. [3 ]
Wasan, H. [4 ]
Argiles, G. [5 ]
Borg, C. [6 ]
Creemers, G. [7 ]
Fedyanin, M. [8 ]
Glynne-Jones, R. [9 ]
Pfeiffer, P. [10 ]
Punt, C. [11 ]
Stroyakovskiy, D. [12 ]
Ten Tije, A. [13 ]
Van de Wouw, A. [14 ]
Kanehisa, A. [15 ]
Fougeray, R. [15 ]
Busto, N. Lopez [15 ]
Amellal, N. [16 ]
Van Cutsem, E. [17 ,18 ]
机构：
[1] Gdansk Med Univ, Szpitale Wojewodzkie Gdyni, Gdynia, Poland
[2] St Petersburg Sci Practical Ctr Specialized Med C, St Petersburg, Russia
[3] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[4] Hammersmith Hosp, Dept Canc Med, London, England
[5] Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona, Spain
[6] Univ Hosp Besancon, Besancon, France
[7] Catharina Hosp, Eindhoven, Netherlands
[8] NN Blokhin Natl Med Res Ctr Oncol, Moscow, Russia
[9] Mt Vernon Ctr Canc Treatment, London, England
[10] Odense Univ Hosp, Dept Oncol, Odense, Denmark
[11] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands
[12] Moscow City Oncol Hosp N62, Moscow, Russia
[13] Amphia Hosp Breda, Breda, Netherlands
[14] VieCuri Med Ctr Noord Limburg, Venlo, Netherlands
[15] Inst Rech Int Servier, Suresnes, France
[16] Servier Oncol, Suresnes, France
[17] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium
[18] Katholieke Univ Leuven, Leuven, Belgium
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
10.1093/annonc/mdy149.021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O - 022
引用
收藏
页码：108 / 108
页数：1
相关论文
共 50 条
  • [1] Phase II study evaluating trifluridine/tipiracil plus bevacizumab and capecitabine plus bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival.
    Van Cutsem, Eric
    Danielewicz, Iwona
    Saunders, Mark P.
    Pfeiffer, Per
    Argiles, Guillem
    Borg, Christophe
    Glynne-Jones, Robert
    Punt, Cornelis J. A.
    van de Wouw, Agnes J.
    Fedyanin, Mikhail
    Stroyakovskiy, Daniil
    Kroening, Hendrik
    Garcia-Alfonso, Pilar
    Wasan, Harpreet Singh
    Falcone, Alfredo
    Aubel, Paul
    Egorov, Anton
    Amellal, Nadia
    Moiseenko, Vladimir
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [2] First-line trifluridine/tipiracil plus bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study
    Van Cutsem, E.
    Danielewicz, I
    Saunders, M. P.
    Pfeiffer, P.
    Argiles, G.
    Borg, C.
    Glynne-Jones, R.
    Punt, C. J. A.
    Van de Wouw, A. J.
    Fedyanin, M.
    Stroyakovskiy, D.
    Kroening, H.
    Garcia-Alfonso, P.
    Wasan, H.
    Falcone, A.
    Fougeray, R.
    Egorov, A.
    Amellal, N.
    Moiseyenko, V
    BRITISH JOURNAL OF CANCER, 2022, 126 (11) : 1548 - 1554
  • [3] First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study
    E. Van Cutsem
    I. Danielewicz
    M. P. Saunders
    P. Pfeiffer
    G. Argilés
    C. Borg
    R. Glynne-Jones
    C. J. A. Punt
    A. J. Van de Wouw
    M. Fedyanin
    D. Stroyakovskiy
    H. Kroening
    P. Garcia-Alfonso
    H. Wasan
    A. Falcone
    R. Fougeray
    A. Egorov
    N. Amellal
    V. Moiseyenko
    British Journal of Cancer, 2022, 126 : 1548 - 1554
  • [4] Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study
    Van Cutsem, E.
    Danielewicz, I
    Saunders, M. P.
    Pfeiffer, P.
    Argiles, G.
    Borg, C.
    Glynne-Jones, R.
    Punt, C. J. A.
    Van de Wouw, A. J.
    Fedyanin, M.
    Stroyakovskiy, D.
    Kroening, H.
    Garcia-Alfonso, P.
    Wasan, H.
    Falcone, A.
    Kanehisa, A.
    Egorov, A.
    Aubel, P.
    Amellal, N.
    Moiseenko, V
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1160 - 1168
  • [5] QoL from TASCO1: Health-related quality of life of trifluridine/tipiracil-bevacizumab and capecitabine-bevacizumab as first-line treatments in metastatic colorectal cancer patients not eligible for intensive chemotherapy-Results from the TASCO1 phase II study.
    Moiseyenko, Vladimir
    Saunders, Mark P.
    Wasan, Harpreet Singh
    Argiles, Guillem
    Borg, Christophe
    Creemers, Geert-Jan
    Fedyanin, Mikhail
    Glynne-Jones, Robert
    Pfeiffer, Per
    Punt, Cornelis J. A.
    Stroyakovskiy, Daniil
    Ten Tije, Albert J.
    de Wouw, Agnes W. Van
    Kanehisa, Akira
    Fougeray, Ronan
    Sabater, Javier
    Amellal, Nadia
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [6] First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design
    Andre, Thierry
    Saunders, Mark
    Kanehisa, Akira
    Gandossi, Eric
    Fougeray, Ronan
    Amellal, Nadia Causse
    Falcone, Alfredo
    FUTURE ONCOLOGY, 2020, 16 (04) : 21 - 29
  • [7] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
  • [8] Updated phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for metastatic colorectal cancer (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Smoljanovic, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Smoljanovic, V
    ANNALS OF ONCOLOGY, 2009, 20 : 76 - 76
  • [10] Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study
    Andre, Thierry
    Falcone, Alfredo
    Shparyk, Yaroslav
    Moiseenko, Fedor
    Polo-Marques, Eduardo
    Csoszi, Tibor
    Campos-Bragagnoli, Arinilda
    Liposits, Gabor
    Chmielowska, Ewa
    Aubel, Paul
    Martin, Lourdes
    Fougeray, Ronan
    Amellal, Nadia
    Saunders, Mark P.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (02): : 133 - 144
12345